

## SUMMARY OF CONFIRMED INFECTIONS

Sanjib Bhattacharyya, PhD  
Laboratory Director

May 2018

Trivikram Dasu, PhD, D(ABMLI)  
Deputy Laboratory Director

### Syphilis

Test	Total	Test	Total
RPR Reactive	2	Darkfield Reactive	0
VDRL Reactive	30	TP-PA Reactive	15

### New Cases of Syphilis

Stage	Number of Cases	
	May 2018	May 2017
Primary syphilis	0	0
Secondary syphilis	0	0
Early latent	0	3
Late latent	0	1
Unknown duration	0	0
Total	0	4

Source: Wisconsin Division of Health

### HIV\*

Test	Total	Positives	Percent (%)
Screening	795	2	0.2
Confirmatory	2	2	100

\*HIV data for 1<sup>st</sup> quarter (Jan-Mar), 2018

### *Chlamydia trachomatis* (CT), *Neisseria gonorrhoeae* (GC), and *Trichomonas vaginalis* (Trich) Nucleic Acid Amplification

Source	CT			GC			Trich		
	Tested	Positives	Percent (%)	Tested	Positives	Percent (%)	Tested	Positives	Percent (%)
Urine	446	53	12	446	30	7	286	14	5
Throat	404	4	1	459	16	3			
Rectal	146	12	8	148	3	2			
Vaginal	0	0	0	0	0	0	60	5	8

### Gonorrhea Antimicrobial Susceptibility Testing

Number Tested	Non-Susceptible (NS) / Decreased-Susceptible (DS) Antibiotics			
	Cefixime	Ceftriaxone	Azithromycin	Gentamicin*
29	0	0	2 (DS)	N/A

\*No CLSI interpretation available

### Clinical Isolates Other Than *N. gonorrhoeae*

Organism	Site	Number Isolates	Organism	Site	Number Isolates
<i>Ureaplasma urealyticum</i>	Genital	3	<i>Neisseria meningitidis</i>	Genital	2
<i>Mycoplasma hominis</i>	Genital	3	<i>Neisseria meningitidis</i>	Non-genital	2

### Clinical and Reference Cultures

Age	Sex	Source	Identification
25	M	Stool	<i>Campylobacter jejuni</i>
57	M	Synovial Fluid	<i>Moraxella nonliquefaciens</i>
7w	M	Mouth	<i>Neisseria meningitidis</i>
7w	M	Mouth	<i>Neisseria meningitidis</i>
23	M	Urine	<i>Neisseria meningitidis</i>

**DNA Sequencing:** The MHD laboratory targets the 16S rRNA and the D2 region of the 28S rRNA genes for sequence-based microbial identification of selective reference bacteria and fungal isolates.

Age	Sex	Source	Target gene	Final Identification
25	M	Stool	16S rDNA	<i>Campylobacter jejuni</i>
23	M	Urine	16S rDNA	<i>Neisseria meningitidis</i>
67	F	BAL	28s rDNA	<i>Scopulariopsis brumptii</i>
78	F	BAL	28s rDNA	<i>Scedosporium apiospermum</i>


### Molecular Amplification

Agent	Method	Tested	Positives	Percent (%)
<i>Bordetella pertussis</i>	Real time PCR	0	0	N/A
Herpes simplex virus	Real time PCR	28	6	21
Influenza virus	Real time RT-PCR	5	2	40
Mumps virus	Real time RT-PCR	2	0	0
Norovirus	Real time RT-PCR	3	3	100
<i>Mycobacterium tuberculosis</i> complex	Real time PCR	0	0	N/A

**Respiratory Pathogens Surveillance:**

Respiratory Pathogen Panel Test Results		
Virus	Positives	Percent (%)
Influenza B	1	8
Human metapneumovirus	3	25
Enterovirus/Rhinovirus	4	33
Adenovirus	3	25
Respiratory Syncytial Virus	1	8
Parainfluenza 4	1	8
Bocavirus	1	8

**Specimens tested: n = 12 (May 2018 – Not including Influenza A PCR data)**



**Note:** The MHDL provides comprehensive detection of multiple respiratory viruses and their subtypes: Influenza A, Influenza B, Respiratory Syncytial Virus (RSV), Human Metapneumovirus (hMPV), Enterovirus/ Rhinovirus (ENT/HRV), Adenovirus, Parainfluenza (HPIV 1-4), Coronavirus and Boca viruses. The bacterial targets include *Chlamydia pneumoniae*, *Mycoplasma pneumoniae*, and *Legionella pneumophila*